The global immunoprotein diagnostic testing market is anticipated to reach USD 10.3 billion by 2025, Research and Markets. This growth can be attributed to the rising incidence of chronic diseases. Technological advancements in the field of immunoprotein diagnostics have led to introduction of novel products. For instance, LIAISON XL, manufactured by DiaSorin, is a fully automated chemiluminescence analyzer that facilitates complete sample processing. It also measures and evaluates testing samples, thereby, enhancing the efficiency and throughput of the system.